

SUPPLEMENTARY TABLE S6. NUMBER OF REPORTED CELL AND TISSUE-ENGINEERED THERAPY TREATMENTS IN EUROPE IN 2017 AND [2016] SORTED BY TYPE OF CLINICAL PROCEDURE

<i>Indications</i>	<i>Clinical procedure</i>		
	<i>Clinical trial</i>	<i>Case study</i>	<i>Routine therapy</i>
Cardiovascular			
Peripheral artery disease	0 [10]	2 [0]	4 [3]
Cardiomyopathy	4 [15]		0 [1]
Heart failure	15 [116]		
Myocardial ischemia	63 [2]		
Decubitus+leg ulcers	0 [17]	10 [62]	
Other	5 [196]		
Musculoskeletal/rheumatological			
Bone repair (maxillofacial)	0 [3]	0 [10]	1 [0]
Bone repair (orthopedics)	9 [58]	6 [7]	0 [3]
Osteogenesis imperfecta	2 [0]		
Cartilage repair (maxillofacial)	0 [23]	0 [12]	
Cartilage repair (orthopedics)	227 [16]	40 [39]	845 [219]
Muscle repair	12 [29]		
Tendon/ligament	36 [4]		0 [33]
Reconstructive surgery/tissue enhancement	3 [7]	1 [17]	7 [24]
Scleroderma	6 [7]	1 [0]	1 [0]
Arthritis	20 [82]	0 [20]	2 [447]
Other	7 [16]	0 [30]	25 [45]
Neurological			
Multiple sclerosis	29 [38]	4 [19]	11 [6]
Amyotrophic lateral sclerosis	46 [18]	6 [1]	0 [1]
Parkinson's	0 [1]		
Peripheral nerve regeneration (trauma)	0 [1]	0 [8]	
Other	48 [57]	30 [6]	1 [1]
Gastrointestinal			
Crohn's disease	0 [15]	0 [2]	
Liver insufficiency	2 [8]	0 [8]	
Hematology/oncology			
Hematological malignancies	169 [146]	37 [67]	1512 [1371]
Solid tumor	86 [90]	0 [24]	4 [3]
Miscellaneous			
Skin reconstruction—burns	1 [10]	0 [1]	43 [323]
Cornea repair	16 [9]	3 [11]	
Diabetes	21 [6]	0 [8]	
Other	13 [84]	0 [19]	299 [566]
Total	840 [1084]	140 [371]	2755 [3046]